Enzon Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 72   

Articles published

ENZN 0.478 +0.008 (1.68%)
price chart
Enzon Pharmaceuticals Inc Stock Upgraded (ENZN)
NEW YORK ( TheStreet) -- Enzon Pharmaceuticals (Nasdaq: ENZN) has been upgraded by TheStreet Ratings from sell to hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by ...
Enzon Pharmaceuticals Inc (ENZN): Warning! Enzon Pharmaceuticals Is Definitely ...
(Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.) Joel Greenblatt's Magic Formula Investing (MFI) screening methodology is an excellent and simple way to find great undervalued stocks ...
Enzon Pharmaceuticals, Inc. (ENZN) Ex-Dividend Date Scheduled for August 13, 2015
will begin trading ex-dividend on August 13, 2015. A cash dividend payment of $0.5 per share is scheduled to be paid on August 12, 2015.
Biotech New Lows: Enzon Pharmaceuticals Inc. (NASDAQ:ENZN), Rexahn ...
Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) was advised by NASDAQ that an ex-dividend date of December 30, 2015 has been established for the $0.25 special cash dividend per share that was announced by the Company on December 3, 2015.
Legendary Investor Icahn Still Slugging Away With Enzon Pharma
Carl C. Icahn has been the principal beneficial shareholder of Icahn Enterprises L.P. (NASDAQ:IEP) and has served as Chairman of the board, a director, and an owner of the company's general partner since 1990. Mr. Icahn heads the investment ...
Related articles »  
Enzon Pharmaceuticals (ENZN) Is Today's Strong On High Volume Stock
Enzon Pharmaceuticals, Inc. engages in licensing drug products. Its marketed drug products include PegIntron for chronic hepatitis C; Sylatron for melanoma; Macugen for neovascular (wet) age-related macular degeneration; and CIMZIA for the treatment of ...
Company Shares of Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) Drops by -3.66%
Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) has lost 3.66% during the past week and dropped 28.21% in the last 4 weeks.
Enzon Pharmaceuticals Inc (NASDAQ:ENZN) Still on Royalty-Driven Autopilot
Enzon Pharmaceuticals Inc (NASDAQ:ENZN, ENZN message board) published a 10-Q report for the quarter ended Mar. 31, 2015 last week, only a few weeks after ENZN hit a 52-week high on the charts, became overbought and subsided again.
Biotech Stocks You Should Dump: Enzon Pharmaceuticals Inc (NASDAQ:ENZN), RXi ...
On the trading floor, shares of Enzon Pharmaceuticals Inc (NASDAQ:ENZN) dropped 1.77% to close at $1.11. The $49.93M company on August 7, 2015 said that “We receive royalty revenues from existing licensing arrangements with other companies ...
Enzon Pharmaceuticals (ENZN) Weak On High Volume Today
Enzon Pharmaceuticals, Inc. engages in licensing drug products. Its marketed drug products include PegIntron for chronic hepatitis C; Sylatron for melanoma; Macugen for neovascular (wet) age-related macular degeneration; and CIMZIA for the treatment of ...